ORA-TESTRYL Drug Patent Profile

Which patents cover Ora-testryl, and when can generic versions of Ora-testryl launch?

Ora-testryl is a drug marketed by Bristol Myers Squibb and is included in one NDA.

The generic ingredient in ORA-TESTRYL is fluoxymesterone. There are three drug master file entries for this compound. Additional details are available on the fluoxymesterone profile page.

Summary for ORA-TESTRYL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	47
Patent Applications:	4,667
DailyMed Link:	ORA-TESTRYL at DailyMed

US Patents and Regulatory Information for ORA-TESTRYL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	ORA-TESTRYL	fluoxymesterone	TABLET;ORAL	011359-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Bristol Myers Squibb	ORA-TESTRYL	fluoxymesterone	TABLET;ORAL	011359-002	Approved Prior to Jan 1, 1982		DISCN	No	No

ORA-TESTRYL: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

ORA-TESTRYL (testosterone undecanoate oral) is a long-acting oral formulation of testosterone developed by Abbott Laboratories, now AbbVie. It is indicated for testosterone replacement therapy in adult males with hypogonadism. The drug's market performance is influenced by the prevalence of hypogonadism, prescribing patterns, competitor landscape, and patent exclusivity.

What is the Current Market Size and Projected Growth for ORA-TESTRYL?

The global market for testosterone replacement therapy (TRT) drugs, including ORA-TESTRYL, is substantial and projected to expand. The prevalence of hypogonadism, often linked to aging, obesity, and metabolic syndrome, directly fuels demand for TRT.

• Estimated Market Size: In 2022, the global TRT market was valued at approximately $3.5 billion [1].
• Projected Growth: The market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 6.5% from 2023 to 2030 [1]. This growth is driven by increasing diagnoses, a growing aging population, and improved patient access to treatment.

ORA-TESTRYL contributes to this market share. While specific revenue figures for ORA-TESTRYL alone are not publicly detailed by AbbVie due to product line reporting, its performance is integrated within the broader testosterone therapy segment. The sustained demand for effective and convenient TRT options supports ORA-TESTRYL's market position.

What is the Competitive Landscape for ORA-TESTRYL?

ORA-TESTRYL competes with a range of testosterone products delivered via different routes, each with distinct advantages and disadvantages impacting market penetration. The primary competitive considerations include efficacy, safety profile, administration convenience, and cost.

• Injectable Testosterone: Products like testosterone enanthate and cypionate are widely used but require periodic intramuscular injections, which can be painful and inconvenient for some patients [2].
• Transdermal Testosterone: Gels, patches, and solutions offer a more continuous delivery system. Examples include AndroGel (AbbVie) and Testim (Auxilium Pharmaceuticals). These avoid injection discomfort but can cause skin irritation or transfer to partners and children [3].
• Other Oral Testosterone Formulations: While ORA-TESTRYL is a significant oral option, other oral testosterone undecanoate products exist. However, the pharmacokinetic profiles and absorption challenges of oral testosterone have historically limited this delivery method until advancements like ORA-TESTRYL.

Key Competitors and Product Types:

• AbbVie: AndroGel (transdermal gel)
• Teva Pharmaceuticals: Testim (transdermal gel)
• Endo Pharmaceuticals: Testopel (testosterone pellets)
• Pfizer: Depo-Testosterone (injectable)
• Various Generic Manufacturers: Offering injectable and, to a lesser extent, transdermal or older oral formulations.

The unique long-acting oral delivery of ORA-TESTRYL differentiates it, offering an alternative to injections and transdermal applications. This differentiation is a key factor in its competitive standing.

What is the Patent Status and Exclusivity for ORA-TESTRYL?

Patent protection is critical for pharmaceutical revenue. ORA-TESTRYL's market exclusivity is governed by its patent portfolio.

• Original Patent Expiration: The foundational patents covering the composition and method of use for ORA-TESTRYL have largely expired in major markets. For instance, key patents in the United States have expired, allowing for generic competition.
• Patent Term Extension: In some regions, patent term extensions may have been granted to compensate for regulatory review periods, temporarily extending market exclusivity [4].
• Generic Entry: Following patent expiration, generic versions of testosterone undecanoate oral formulations can enter the market, typically leading to a significant reduction in pricing and market share for the originator product.
• Formulation Patents: While composition patents may expire, specific formulation or manufacturing process patents could potentially extend some degree of protection, though these are generally less robust than composition patents.

Impact of Generic Competition: The entry of generic testosterone undecanoate products directly challenges ORA-TESTRYL's market share and pricing power. Generic manufacturers can offer lower-cost alternatives, attracting price-sensitive prescribers and payers. AbbVie's strategy to maintain revenue often involves lifecycle management, including the development of next-generation products or focusing on established brand loyalty.

What are the Key Regulatory Considerations and Approvals?

Regulatory approval is a prerequisite for market entry and influences a drug's commercial viability. ORA-TESTRYL has undergone rigorous review processes in major pharmaceutical markets.

• United States FDA Approval: ORA-TESTRYL received FDA approval for the treatment of hypogonadism in adult males. The approval was based on clinical trials demonstrating its efficacy in restoring testosterone levels and improving associated symptoms.
• European Medicines Agency (EMA) Approval: ORA-TESTRYL is also approved for use in the European Union, following EMA review.
• Other Jurisdictions: Approvals have been secured in other key global markets, with specific regulatory pathways and requirements varying by country.

Post-Market Surveillance and Labeling: Like all pharmaceuticals, ORA-TESTRYL is subject to ongoing post-market surveillance. Any new safety concerns or efficacy findings can lead to label changes, prescribing restrictions, or in rare cases, market withdrawal. AbbVie must adhere to these regulatory requirements to maintain its product's standing.

What is the Financial Performance and Revenue Outlook for ORA-TESTRYL?

Detailed financial reporting specifically for ORA-TESTRYL is not typically disaggregated by AbbVie in their public financial statements. The drug's performance is usually aggregated within broader product categories, such as "Endocrinology" or "Testosterone Products." However, general market trends provide insights into its potential financial trajectory.

• Revenue Contribution: ORA-TESTRYL's revenue contribution is linked to its market share within the oral TRT segment and the overall TRT market. Its long-acting oral formulation provides a competitive edge against some traditional delivery methods.
• Impact of Genericization: As patent exclusivity wanes and generic versions become available, revenue for originator products typically declines due to price erosion and increased competition. This is a significant factor for ORA-TESTRYL's future financial outlook.
• Market Dynamics: The increasing prevalence of hypogonadism and a growing acceptance of TRT among healthcare providers and patients are positive drivers. However, the pressure from generic competition and alternative therapies, including newer delivery systems, moderates revenue growth.

Projected Financial Trajectory (Qualitative):

• Current Period: ORA-TESTRYL likely continues to generate significant revenue, benefiting from its established brand and unique delivery profile in markets where patents still offer some protection or where generic adoption is gradual.
• Near-to-Mid Term (2-5 years): Revenue is expected to face increasing pressure from generic competition as patent expiries become more widespread. Price erosion will be a primary concern.
• Long Term (5+ years): Revenue contribution will likely be significantly reduced as generics capture a substantial market share. AbbVie's focus may shift to newer pipeline products or other revenue streams.

Factors Influencing Future Revenue:

• Aggressiveness of Generic Manufacturers: The speed and volume of generic entry.
• Payer Policies: Reimbursement rates and formulary placement for ORA-TESTRYL versus generics.
• Physician Prescribing Habits: The inertia of physicians to switch from established brands to generics.
• Development of Alternative Therapies: Innovations in TRT delivery or novel treatment modalities.

Key Takeaways

ORA-TESTRYL operates within a growing but highly competitive testosterone replacement therapy market. Its long-acting oral formulation provides a differentiated profile, but this advantage is being steadily eroded by the expiration of key patents and the subsequent entry of generic competitors. While the overall demand for TRT is increasing due to rising hypogonadism prevalence, ORA-TESTRYL's financial trajectory is expected to face significant headwinds from price erosion and market share loss to lower-cost generic alternatives in the coming years. AbbVie's ability to manage this transition will be crucial for its continued profitability in this segment.

Frequently Asked Questions

1. What specific advantages does ORA-TESTRYL offer over injectable testosterone therapies? ORA-TESTRYL offers the advantage of oral administration, eliminating the need for injections, which can be associated with pain, inconvenience, and the risk of infection at the injection site. Its long-acting formulation also ensures more stable testosterone levels compared to some shorter-acting injectable esters.

2. How does ORA-TESTRYL compare in efficacy to transdermal testosterone gels and patches? Clinical studies have demonstrated comparable efficacy of ORA-TESTRYL to transdermal testosterone in restoring physiological testosterone levels and improving hypogonadism symptoms. However, individual patient responses and side effect profiles can vary between delivery methods, influencing prescriber and patient preference.

3. What is the primary mechanism of action for ORA-TESTRYL in treating hypogonadism? ORA-TESTRYL works by delivering testosterone undecanoate, a synthetic ester of testosterone, into the bloodstream. After absorption, it is hydrolyzed to release testosterone, thereby replenishing the body's endogenous testosterone levels and alleviating the symptoms of hypogonadism.

4. Are there any specific contraindications or significant side effects associated with ORA-TESTRYL that differentiate it from other testosterone therapies? Like other testosterone products, ORA-TESTRYL has contraindications, including known or suspected pregnancy, breastfeeding, prostate cancer, or male breast cancer. Common side effects can include abdominal pain, diarrhea, and nausea, which are related to its oral administration. It's crucial for patients to be monitored for potential cardiovascular risks, liver function abnormalities, and other testosterone-related adverse events.

5. What strategies can pharmaceutical companies employ to mitigate the financial impact of patent expiration for a drug like ORA-TESTRYL? Strategies include developing next-generation formulations with improved profiles, exploring new indications, focusing on established brand loyalty and patient support programs, and managing the transition to authorized generics or biosimilars if applicable. Investing in pipeline development for entirely new therapeutic agents also diversifies revenue streams.

Citations

[1] Grand View Research. (2023). Testosterone Replacement Therapy Market Size, Share & Trends Analysis Report By Product (Injectable, Transdermal, Oral, Implants), By Age Group (25-49 Years, 50-64 Years, 65+ Years), By Disease (Hypogonadism, Klinefelter Syndrome, Pituitary Disorders), By End-use (Hospitals, Clinics, Home Care), By Region, And Segment Forecasts, 2023 - 2030.

[2] Shabsigh, R., & Kang, J. (2009). Testosterone therapy in hypogonadal men. The Journal of Urology, 182(3), 1231-1239.

[3] Nieschlag, E., Swerdloff, R., Behre, C., et al. (2004). Andrology. The Lancet, 363(9406), 469-480.

[4] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA website] (Specific patent expiration dates are not publicly listed in a consolidated manner for individual drugs in the Orange Book, requiring patent specific research for definitive dates.)